Bayer's Q3 Test: JPMorgan Sees Revenue Beat but Weaker EBITDA, as Pipeline News Carries the Story

Ahead of Bayer's third-quarter 2026 report, JPMorgan is telling clients to expect a company that sells more than the market anticipates — but earns less from it. Analyst Richard Vosser projects revenue roughly 2% above consensus, while his EBITDA estimate sits about 6% below it. The US bank reaffirmed its "Overweight" rating and a price target of EUR 61, signaling that the divergence between business volume and profitability, not a shift in recommendation, is where the real question lies.

Vosser also expects Bayer to stand by its full-year guidance. That matters: a softer profit call is not the same as a warning, and no downgrade to the annual outlook is baked into his numbers. It is worth keeping in mind that a gap versus consensus simply measures the distance to other analysts' expectations — it is neither a reported figure nor automatically a year-on-year change. Even the anticipated guidance confirmation remains a forecast.

The November Date That Settles the Argument

Bayer has scheduled its Q3 2026 results for November 3, with the release due from 7:30 a.m. CET. That morning will show whether Vosser's predicted mix — stronger sales, weaker EBITDA — actually materializes. Revenue alone would tell an incomplete story; how management frames operating profit and the rest of the year will carry equal weight. JPMorgan's bullish stance does not remove that checkpoint. It sits explicitly alongside the sub-consensus EBITDA call.

Against that backdrop, the pipeline has been supplying its own headlines. On October 8, the FDA accepted Bayer's supplemental application for Finerenon in chronic kidney disease in adults without diabetes, backed by the Phase III FIND-CKD study. Acceptance, however, is not approval — a distinction that matters when translating regulatory milestones into earnings power. Positive trial data and a filing under review describe a drug's development path, not the contribution it has already made to the bottom line.

A First Patient Dosed, and a $2.2 Billion Bet on Ohio

Bayer's subsidiary Vividion is also moving forward clinically: the first patient has been treated in a Phase II combination study pairing the WRN inhibitor VVD-214 with Pembrolizumab. The trial targets previously untreated patients with advanced MSI-high or dMMR colorectal cancer. Enrollment of a single patient expands the development program but says nothing yet about the combination's efficacy.

Further out on the horizon, Bayer unveiled plans roughly two weeks ago for a new pharmaceutical production site in New Albany, Ohio — a $2.2 billion investment expected to create around 600 jobs. It is a long-term manufacturing decision that complements the drug-development news, and it remains a planned buildout rather than a completed one.

Two Analyst Views, One Quarter

Analyst Matthew Weston pointed to intact Crop Science trends for 2026 and 2027, along with momentum in the pharma business. That constructive read coexists with the recently trimmed near-term profit estimates — media reports indicated Q3 earnings forecasts had fallen on Tuesday. The two threads should be assessed separately: a positive analyst verdict is not the same as cautious expectations for the coming quarter.

When the November 3 report lands, it will be the next opportunity to square operating performance with those expectations. Until then, the pharma headlines mainly document progress on the development front — they do not substitute for business figures. Keeping that line clear is what the latest round of news ultimately demands.